the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Tumor Clinical Trial

Official title:
Comparison of the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: a Prospective, Randomized Controlled Phase II Clinical Trial

Status Recruiting

Clinical Trial Summary

To compare the efficacy and safety of megestrol acetate dispersible tablets combined with 5-HT3 receptor antagonist and dexamethasone triple antiemetic regimen and 5-HT3 receptor antagonist and dexamethasone combined antiemetic regimen in the control of CINV induced by hyperemetic chemotherapy.

Clinical Trial Description

120 patients with malignant tumors diagnosed by pathology or cytology and treated with highly emetogenic chemotherapy drugs containing cisplatin from September 2018 to December 2019 were selected. The patients were randomly assigned to megestrol group (megestrol acetate dispersible tablets+5-HT3 receptor antagonist+dexamethasone) or control group (5-HT3 receptor antagonist + dexamethasone) at 1:1. The dosage of antiemetic drugs in the control group: 5-HT3 receptor antagonist 2.5mg, dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, all were injected intravenously with 30min before chemotherapy for 5 days. The patients in the megestrol acetate group were given megestrol acetate dispersible tablets on the basis of the control group. 160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days. The main end point was the proportion of control of nausea and vomiting between the two groups during the delayed period (24-120 hours after the beginning of chemotherapy), that is, the proportion of complete remission (no vomiting and no need for rescue treatment) and complete prevention (no nausea and vomiting).The secondary end point was the control ratio of nausea and vomiting in the acute phase (0-24 hours after the beginning of chemotherapy) and the overall phase (0-120 hours after the beginning of chemotherapy); the proportion of patients with grade 3-4 nausea and vomiting during chemotherapy; the adverse reactions related to antiemetic drugs and the score of quality of life of patients in both groups before and after treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04430361
Study type	Interventional
Source	Henan Cancer Hospital
Contact	Ning Li
Phone	13526501903
Email	lining97@126.com
Status	Recruiting
Phase	Phase 2
Start date	September 7, 2018
Completion date	May 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04848376` - Post-Market Clinical Follow-up Study of A-SPINE's Products
Active, not recruiting	`NCT05470283` - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma	Phase 1
Completed	`NCT05041920` - A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects	Phase 1
Not yet recruiting	`NCT05549557` - IMM40H Phase I Dose Escalation and Expansion	Phase 1
Not yet recruiting	`NCT05443854` - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)	Phase 3
Completed	`NCT01946555` - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain	N/A
Terminated	`NCT01846429` - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain	Phase 1
Recruiting	`NCT01093079` - Laparoscopic Versus Open Partial Nephrectomy - Surgical and Oncological Outcomes	N/A
Recruiting	`NCT01387971` - Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders	N/A
Recruiting	`NCT00690261` - The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction	N/A
Completed	`NCT00561795` - Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors	Phase 2
Completed	`NCT00413322` - Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00152659` - Developing Criteria for Cortical Resections
Completed	`NCT00777751` - Radiation Therapy and Cardiac Enzymes	N/A
Not yet recruiting	`NCT06109896` - Clinical Stories and Psychological Experiences of Cancer Patients
Not yet recruiting	`NCT05879146` - Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study	Phase 2
Recruiting	`NCT02810405` - Collection of Tissue Blocks or Slides From Patients With Cancer
Recruiting	`NCT01867268` - Effect of Acetazolamide & Position in CSF Leakage and Collection and Wound Dehiscence	Phase 2
Terminated	`NCT01720745` - Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA
Completed	`NCT01919710` - Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia	Phase 1